An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Frequency Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Frequency Therapeutics, Inc. (NASDAQ: FREQ) announced that CEO David L. Lucchino will present at two upcoming investor conferences. The H.C. Wainwright 23rd Annual Global Investment Conference will be available for on-demand viewing from September 13, 2021, at 7:00 a.m. ET. Additionally, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit is scheduled for September 22, 2021, at 8:15 a.m. ET. The presentations can be accessed via the investors section of Frequency's website, where replays will also be available.
Positive
None.
Negative
None.
LEXINGTON, Mass.--(BUSINESS WIRE)--
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present at the following investor conferences:
H.C. Wainwright 23rd Annual Global Investment Conference: On-demand viewing will start Monday, September 13, 2021 at 7:00 a.m. ET
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit:Wednesday, September 22, 2021 at 8:15 a.m. ET
A webcast of the presentations may be accessed on the investors section of Frequency’s website, investors.frequencytx.com. A replay of each presentation will be posted to the Frequency website following the event.
About Frequency Therapeutics
Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. FX-322 is being evaluated in multiple ongoing clinical studies in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including in a pre-clinical program in multiple sclerosis.
Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.
What are the dates of Frequency Therapeutics' upcoming investor presentations?
Frequency Therapeutics will present at the H.C. Wainwright Global Investment Conference on September 13, 2021, and at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021.
Where can I watch Frequency Therapeutics' investor presentations?
The presentations will be available for on-demand viewing on the investors section of Frequency Therapeutics' website following the events.
What is the focus of Frequency Therapeutics?
Frequency Therapeutics focuses on developing therapies that activate progenitor cells to repair or regenerate damaged tissues, particularly for degenerative diseases.
What is Frequency Therapeutics' lead product candidate?
The lead product candidate of Frequency Therapeutics is FX-322, which aims to regenerate auditory hair cells to restore hearing function.
Is FX-322 being tested for any conditions?
Yes, FX-322 is being evaluated in clinical studies for patients with sensorineural hearing loss.
Who is the CEO of Frequency Therapeutics?
The CEO of Frequency Therapeutics is David L. Lucchino.
